Mst1 and Mst2 Maintain Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development through Inactivation of the Yap1 Oncogene

Dawang Zhou,1,2 Claudius Conrad,3,4,11 Fan Xia,1,2,11 Ji-Sun Park,3 Bernhard Payer,1,6 Yi Yin,1,2 Gregory Y. Lauwers,5,8 Wolfgang Thasler,10 Jeannie T. Lee,1,6,8,9 Joseph Avruch,1,2,7,* and Nabeel Bardeesy3,7,*

1Department of Molecular Biology
2Diabetes Unit
3Cancer Center
4Surgical Services
5Department of Pathology
6Howard Hughes Medical Institute
Massachusetts General Hospital, Boston, MA 02114, USA
7Department of Medicine
8Department of Pathology
9Department of Genetics
Harvard Medical School, Boston, MA 02115, USA
10Department of Surgery, LM University Munich, Hospital Grosshadern, D-81377 Munich, Germany
11These authors contributed equally to this paper
*Correspondence: avruch@molbio.mgh.harvard.edu (J.A.), nelbardeesy@partners.org (N.B.)
DOI 10.1016/j.ccr.2009.09.026

SUMMARY

Hippo-Lats-Yorkie signaling regulates tissue overgrowth and tumorigenesis in Drosophila. We show that the Mst1 and Mst2 protein kinases, the mammalian Hippo orthologs, are cleaved and constitutively activated in the mouse liver. Combined Mst1/2 deficiency in the liver results in loss of inhibitory Ser127 phosphorylation of the Yorkie ortholog, Yap1, massive overgrowth, and hepatocellular carcinoma (HCC). Reexpression of Mst1 in HCC-derived cell lines promotes Yap1 Ser127 phosphorylation and inactivation and abrogates their tumorigenicity. Notably, Mst1/2 inactivates Yap1 in liver through an intermediary kinase distinct from Lats1/2. Approximately 30% of human HCCs show low Yap1(Ser127) phosphorylation and a majority exhibit loss of cleaved, activated Mst1. Mst1/2 inhibition of Yap1 is an important pathway for tumor suppression in liver relevant to human HCC.

INTRODUCTION

Mst1 and Mst2 are 56–60 kDa class 2 GC kinases that share 76% identity in amino acid sequence (Dan et al., 2001). Mst1/2 are the closest mammalian homologs of the Drosophila Hippo kinase. Loss of Hippo function (in the fly eye) results in massive overgrowth, due to an acceleration of cell cycle progression and a failure of developmental apoptosis (Harvey et al., 2003; Udan et al., 2003; Wu et al., 2003); Mst2 can complement Hippo loss of function (Wu et al., 2003). The pathway downstream of Hippo has been extensively characterized (Reddy and Irvine, 2008; Zhao et al., 2008a); Hippo, when bound to the adaptor protein Salvador/Shar-pei, phosphorylates the Lats/Warts kinase. Hippo also phosphorylates the noncatalytic polypeptide Mats (Mob as tumor suppressor), enabling the latter to promote Lats/Warts autophosphorylation and activation. Active Lats/Warts in turn

SIGNIFICANCE

The pathways that regulate quiescence and tumor suppression in the liver have not been fully elucidated. We show that the Mst1 and Mst2 kinases are tumor suppressors and regulators of liver size in adults and that negative regulation of the transcriptional coactivator, Yap1, is central to Mst1/2 tumor-suppressor function. Loss of both Mst1 and Mst2 is sufficient to initiate hepatocyte proliferation, resulting in dramatic liver overgrowth, resistance to proapoptotic stimuli, and the development of HCC. Mst1 and Mst2 promote phosphorylation of Yap1 and thereby suppress its oncogenic activity. Mst1/2 regulation of Yap1 is tissue specific and, in the liver, involves an Mst1/2-regulated Yap1 kinase distinct from Lats1/2. Significantly, the Mst-Yap1 pathway is disrupted in a substantial fraction of human HCCs.
phosphorylates and inhibits the transcriptional coregulator Yorkie, by promoting its binding to 14-3-3 and nuclear exit (Dong et al., 2007). Yorkie’s actions are pro-proliferative and antiapoptotic, and elimination of Yorkie is epistatic to loss of function of all of the upstream elements named above (Huang et al., 2005). The regulation of Hippo kinase activity is less well defined, although elimination of the atypical cadherin, Fat, or both of the FERM domain proteins, Merlin and Expanded, results in Yorkie-dependent phenotypes resembling Hippo loss of function (Reddy and Irvine, 2008).

Essentially all of these components have mammalian orthologs, and the ability of Mst1/2 to phosphorylate Lats1/2 and Mob1, as well as Lats1 phosphorylation and inhibition of Yap1, the mammalian ortholog of Yorkie, have been observed in vitro and in cell culture (Chan et al., 2005; Dong et al., 2007; Hao et al., 2008; Praskova et al., 2008; Zhao et al., 2007). In addition, cell-cell contact of cultured mammalian cells induces phosphorylation and inactivation of Yap1, whereas overexpression of Yap1 or inactivation of eithers Lats2 or NF2/Merlin bypasses contact inhibition of growth (McPherson et al., 2004; Morrison et al., 2001; Zhao et al., 2007). Similarly, mouse keratinocytes lacking WW45, the ortholog of Salvador/Shar-pei, fail to activate Mst1, phosphorylate Yap1, and exit the cell cycle during differentiation in vitro (Lee et al., 2008). Consistent with a function as tumor suppressors, inactivating mutations in NF2 and WW45 have been observed in a number of human cancers, and Lats1 knockout mice develop soft tissue sarcomas and ovarian cancers (McClatchey and Giovannini, 2005; McPherson et al., 2004; Tapon et al., 2002). Yap1 is amplified in a number of human tumor types and transgenic overexpression of Yap1 in mice leads to liver overgrowth and hepatocellular carcinoma (HCC) as well as expansion of progenitor cells in multiple organs (Camargo et al., 2007; Dong et al., 2007; Overholtzer et al., 2006; Zender et al., 2006). Whether Yap1 is regulated by the mammalian Hippo pathway in vivo and whether loss of function of the growth inhibitory components of the pathway results in defects in organ size regulation has not been established.

Recent insight into the physiologic role of Mst1 has come from the phenotype of Mst1-deficient mice, and here a rather different picture emerges from that predicted from the Hippo paradigm (Katagiri et al., 2009; Zhou et al., 2008). Mst1-deficient mice exhibit greatly diminished numbers of mature, naive T cells in peripheral lymphoid organs associated with defects in adhesion and migration of the Mst1 null T cells. In addition, Mst1 null naive T cells overproliferate upon stimulation of the T cell antigen receptor. T cell adhesion requires the chemokine-induced clustering and activation of integrins such as LFA-1; the latter, in turn, requires the Rap1-GTP-dependent recruitment and activation of Mst1 through its regulatory subunit, Nore1B (also called RasS5B or RAPL), a Ras/Rap1-GTP binding protein (Avruch et al., 2009; Katagiri et al., 2006). The Mst1 substrate(s) mediating LFA-1 clustering/activation and the antiproliferative effects in naive T cells are unknown. Although Mob1 phosphorylation is abolished in the Mst1 null T cells, Mst1 deficiency causes little or no change in the TCR-regulated phosphorylation of Lats1/2 and Yap1 (Zhou et al., 2008). Taken together, these findings indicate that Mst1 and Mst2 participate in at least two signal transduction pathways, perhaps in a tissue-specific manner, each involving distinct upstream regulators and at least some different targets. Both pathways, however, generate antiproliferative outputs, suggesting that Mst1 and/or Mst2 may serve to suppress tumor initiation. Here, we investigate the functions of Mst1/2 in growth control, tumorigenesis, and Yap1 regulation in vivo using genetically engineered mice.

RESULTS

Mst1 and Mst2 Are Required for Embryonic Development and to Suppress HCC

We generated mouse strains with germline deletion of Mst1 and Mst2 (Mst1−/− and Mst2−/− alleles) (Zhou et al., 2008; see Figure S1, available online); all studies were performed on a mixed (75%–87.5% C57B/6) genetic background. Mst1−/− mice were viable and fertile but had a reduced number of mature naive T cells as reported previously (Zhou et al., 2008); Mst2−/− mice exhibit no developmental or immunological defects and normal fertility. Over a period of 18–24 months, 2/23 Mst1−/− mice developed lethal histiocytic sarcomas and 1/15 Mst2−/− mice developed a mammary tumor, whereas all wild-type mice (n = 15) remained healthy.

To evaluate the genetic interaction between Mst1 and Mst2 deficiency, we intercrossed the Mst1 and Mst2 knockouts. The Mst1+/−Mst2−/−, Mst1−/−Mst2−/−, and Mst1+/−Mst2−/− animals were viable, were fertile, and showed no developmental anomalies (Figure S2). The Mst1−/−Mst2−/− genotype, however, resulted in embryonic lethality with first signs of retardation evident at embryonic day 8.5 (E8.5) (Figure 1A). By E9.5 Mst1−/−Mst2−/− embryos were severely compromised (Figure 1A) and not detected thereafter (Figure S2). Hence, a single functional copy of Mst1 or Mst2 is both necessary and sufficient for normal mouse development.

Necropsy at 3 and 5 months of age did not reveal obvious defects in any of the viable genotypes. However, starting at 7 months of age, Mst1−/−Mst2−/− mice began to show signs of illness, including lethargy and presence of a palpable abdominal mass (the survival curve is shown in Figure 1B). Mst1+/−Mst2−/− animals showing morbidity (n = 13 of 16 animals by age 15 months) were euthanized and necropsies revealed that all mice harbored liver tumors (ranging from 0.5 to 1.5 cm in greatest diameter; Figure 1C). Some of these mice also displayed overgrowth (2- to 4-fold) of the apparently normal liver tissue. Lethal liver tumors were also observed in 3/12 Mst1−/−Mst2−/− mice by 15 months of age. Histological examination revealed that the liver tumors in the Mst1/2 mutant mice were highly aggressive hepatocellular carcinomas (HCCs) (Figure 1D). To further document the incidence of HCC, we performed necropsies on 7-month-old asymptomatic animals. We observed HCCs in 6/7 Mst1−/−Mst2−/− mice, whereas none of the wild-type animals (n = 7) or Mst1+/−Mst2−/− mice (n = 6) had visible tumors.

Dual Inactivation of Mst1 and Mst2 in HCC

PCR analysis of HCCs from Mst1−/−Mst2−/− mice revealed the absence of wild-type Mst2, whereas adjacent normal liver remained heterozygous for Mst2 (Figure 1E). Similarly, tumor-specific loss of the wild-type Mst1 allele was seen in HCCs from Mst1−/−Mst2−/− mice (Figure S3). Correspondingly, Mst1 and Mst2 proteins were undetectable in all HCCs analyzed, as assessed by western blotting (Figure 1F, left, and data not
Previous studies have shown that the truncated form of normal liver, of 34 kDa amino-terminal fragment Mst1 protein—and a substantial fraction of Mst2—in extracts show an expression of Mst1 and Mst2. Unexpectedly, the majority of shown). In comparison, liver from wild-type mice showed robust expression of Mst1 and Mst2. Unexpectedly, the majority of Mst1 protein—and a substantial fraction of Mst2—in extracts of normal liver is in the form of 34 kDa amino-terminal fragment (Figure 1F, left). Previous studies have shown that the truncated 34 kDa form of Mst1 can arise from caspase-dependent cleavage in response to apoptotic (Cheung et al., 2003; Graves et al., 1998; Ura et al., 2001) or cell differentiation (Fernando et al., 2002) signals and that this form has increased kinase activity and altered substrate specificity (Anand et al., 2008). Notably, we observe high levels of Mst1/2 activation in the normal liver (as judged by phosphorylation at the Ser183/180 site; Praskova et al., 2004) and that the vast majority of the active Mst1/2 kinase is in the form of the 34 kDa fragment (Figure 1F). Although the 34 kDa polypeptide undergoes proteolytic degradation during Mst1 immunoprecipitation (seen as a ladder of polypeptides of faster mobility; Figure 1F, right), the majority of the of the immunoprecipitated anti-pMst1(Ser183) immunoreactivity is retrieved with the 34 kDa polypeptide, confirming its identity as the cleaved, activated form of Mst1. In the spleen, only full-length Mst1 and Mst2 are observed (Figure 1G). These results indicate that Mst1 and Mst2 are constitutively activated in the quiescent adult liver and that homozygous inactivation of both of these kinases in liver cells results in progression to HCC. Hence Mst1 and Mst2 have partially redundant functions and serve as critical HCC tumor suppressors. In addition, it appears that tissue-specific cleavage may be an important mechanism of Mst1/2 regulation in vivo.

Mst1 and Mst2 Are Critical Regulators of Quiescence and Organ Size in the Adult Liver

To explore in more detail the role of Mst1 and Mst2 in liver homeostasis, we sought to generate mice with homozygous deficiency of both of these genes in the liver. To this end, we introduced an Mst2 conditional knockout allele (Mst2F) onto an Mst1 and Mst2 germline null background (generating Mst1+/−Mst2F/F mice and Mst1−/−Mst2F/− mice). Adenovirus expressing Cre recombinase (Adeno-Cre) was injected into the tail vein
of these mice at an age of 6 weeks to induce liver-specific deletion of Mst2; as controls, wild-type and Mst1\(^{-/-}\)Mst2\(^{-/-}\) mice were also injected with Adeno-Cre. We confirmed the ~90% reduction of Mst2 in the livers of Adeno-Cre-injected Mst1\(^{-/-}\)Mst2\(^{-/-}\) or Mst1\(^{-/-}\)Mst2F/F mice (designated Mst1/2 null livers) compared to wild-type livers (Figure 2A). Remarkably, analysis at serial time points revealed massive overgrowth of the Mst1/2 null livers. As early as 3 days after Adeno-Cre administration, a prominent increase in liver size was noted (data not shown). The Mst1/2 null livers were 2-fold larger than those from Adeno-Cre-injected control animals at 8 days and 4-fold larger by 3 months (Figures 2B and 2C). Ki-67 staining at day 8 showed that the Mst1/2 null livers had an ~4-fold increase in hepatocyte proliferation (Figures 2D and 2E). These data establish Mst1 and Mst2 as critical regulators of quiescence and organ size in the adult liver.

The loss of the wild-type Mst1 and Mst2 alleles in the spontaneous HCC models described above suggested that complete loss of Mst1/2 signaling in liver cells might be a rate-limiting step in HCC pathogenesis. Correspondingly, Mst1\(^{-/-}\)Mst2F/F and Mst1\(^{-/-}\)Mst2F/− mice developed lethal liver tumors with a mean latency of 10 weeks after Adeno-Cre injection (Figures 2F and 2G). Histological examination revealed the presence of multifocal HCCs against the backdrop of hyperplastic, but untransformed, hepatocytes (Figure 2G).

To further validate the Mst1/2 tumor-suppressor function in hepatocytes, we crossed the Mst1/2 mutants with the Albumin-Cre transgenic strain that specifically targets hepatocytes. Whereas control mice showed no abnormalities, we found that 4/4 Albumin-Cre Mst1\(^{-/-}\)Mst2F/F mice developed massively overgrown livers and HCC by 3 months of age (Figure S4). The tumor-specific loss of heterozygosity in the spontaneous HCC models and the accelerated tumor development associated with homozygous inactivation of both Mst1 and Mst2 in hepatocytes together suggest that Mst1/2 suppress HCC at least in part through cell-autonomous mechanisms.
Mst1/Mst2 Regulate Liver Size and Tumorigenesis

Mst1/2-Independent Regulation of Yap1 in MEFs

Previous in vitro studies have shown that cellular contact induces Ser127 phosphorylation and cytoplasmic retention of Yap1 and that this regulatory pathway is important for contact inhibition of proliferation (Zhao et al., 2007). The prevailing view has been that the core Hippo pathway components are required to regulate Yap1 phosphorylation and activity in mammalian cells (Dong et al., 2007; Zhao et al., 2008a). However, the specific requirement of individual pathway components in normal tissues has not been tested (apart from T cells; Zhou et al., 2008). Moreover, whether the pathway of Yap1 regulation is universal or has context-dependent circuitry has not been established. First, we sought to investigate the role of Mst1/2 in Yap1 regulation using immortalized mouse embryonic fibroblasts (MEFs). Consistent with published results we found that increasing cell density induced Yap1(Ser127) phosphorylation in wild-type MEFs (Figure 3A). Unexpectedly, basal and cell contact-induced Yap1(Ser127) phosphorylation was unimpaired in Mst1−/−Mst2−/− MEFs (generated by infection of MEFs from Mst1−/−Mst2F/F mice with a retrovirus-expressing Cre recombinase) although these cells lost Mob1(Thr12) phosphorylation (Figures 3A and 3C). Notably, in wild-type MEFs, Mst1 and Mst2 are present exclusively as full-length polypeptides lacking detectable active site phosphorylation and confluence is not accompanied by detectable change in the phosphorylation of Mst1/2 or of Mob1(Thr12) (Figure 3B). As with Yap1(Ser127) phosphorylation, Lats1/2 activation loop (AL) phosphorylation was induced at high cell density regardless of Mst1/2 status (Figure 3C). Identical results were observed in primary (nonimmortalized) MEFs except that confluence induced clearcut Lats1/2 carboxy-terminal phosphorylation in the primary MEFs (Figure S6). In parallel with the contact-induced phosphorylation of Yap1(Ser127), both wild-type and Mst1−/−Mst2−/− MEFs showed cytoplasmic translocation of Yap1 when grown to high cell density (Figure 3D). Correspondingly, the Mst1−/−Mst2−/− MEFs exhibited normal contact inhibition of proliferation (data not shown). The present unexpected results demonstrate that in MEFs, Mst1/2 are not the upstream regulators of Lats1/2 and Yap1 in response to cell-cell contact.

Mst1/2 Inactivation in the Liver Results in Deregulation of Mob1 and Yap1 but Not Lats1/2

Our results in MEFs indicate that either Mst1/2 do not have a conserved function in regulating Lats/Yap1 or that the pathway upstream of Yap1(Ser127) phosphorylation is operative in a tissue- or context-specific manner. The Adeno-Cre system provided an opportunity to study the early signaling events accompanying acute ablation of Mst1/2 in the liver. We found that the Mst1/2 null livers had sharp decreases in pMob1(Thr12) and pYap1(Ser127) at the 3 and 8 day time points as well as in the ensuing HCCs (Figure 4A). Levels of total Yap1 polypeptide were increased following Mst1/2 inactivation (Figure 4A), whereas Yap1 mRNA levels were unchanged (data not shown), suggesting that the unphosphorylated form of Yap1 may be stabilized. Unexpectedly, phosphorylation of Lats1/2 at the carboxy-terminal and activation loop was minimally altered in the Mst1/2 null livers and was at comparable levels in HCC and normal liver. Ndr1 and Ndr2 are the most closely related kinases to Lats1/2 and can also be activated by Mst1/2-mediated carboxy-terminal phosphorylation (Vichalkovski et al., 2008). Mst1/2 inactivation resulted in a modest decrease in Ndr1/2 carboxy-terminal and activation loop phosphorylation (Figure 4A). These patterns were also observed in livers and HCC from Albumin-Cre; Mst1−/−Mst2F/F mice indicating that such changes were not a secondary consequence of the Adeno-Cre infection (Figure 4B).

Consistent with the role of Yap1(Ser127) phosphorylation in cytoplasmic retention of Yap1, cell fractionation experiments revealed that Yap1 is almost entirely cytoplasmic in wild-type liver but present at high abundance in the nuclei of Mst1/2 null liver (Figure 4C, top panel) and almost entirely nuclear in HCC (Figure 4C, bottom panel). Immunohistochemical analysis confirmed the overexpression and nuclear translocation of Yap1 in HCC (Figure 4D). Moreover, the expression of the candidate Yap1 target genes, CTGF and AFP (Dong et al., 2007; Zhao et al., 2008b), was significantly elevated in the Mst1/2 null liver and in HCC (Figure 4E). Together, these data demonstrate that Mst1 and Mst2 are critical negative regulators of Yap1 activity in hepatocytes in vivo and moreover suggest that a kinase other than Lats1/2 may be responsible for Yap1 phosphorylation downstream of Mst1/2. Inasmuch as Yap1 overexpression has been shown to promote liver overgrowth and HCC, it is likely that the deregulation of Yap1 activity contributes to these phenotypes in the Mst1/2 mutant mice.

To gain further insight into the identity of the hepatic Yap1 kinase, we fractionated mouse liver extracts by anion exchange chromatography. The Yap1(Ser127) kinase activity of each column fraction was assayed against prokaryotic recombinant
Yap1, using the phosphospecific anti-Yap1(Ser127-P) antibody to detect kinase activity (Figure 4F). In addition to the elution of endogenous hepatic Yap1(Ser127-P), two peaks of Yap1(Ser127) kinase activity were observed in chromatograms from wild-type mouse liver (Figure 4F, arrow; fractions 13–15 and 20–23). Note that the later-eluting of these peaks of Yap1 kinase activity comigrates with Lats1, whereas neither peak coelutes with Lats2. We next compared the chromatograms of wild-type and Mst1/2 null liver extracts prepared 8 days after injection of Adeno-Cre (Figure 4G). We found that the earlier-eluting peak of Yap1(Ser127) kinase was entirely absent from the Mst1/2 null liver, whereas the later-eluting peak of Yap1(Ser127) kinase, which co-elutes with Lats1 (Figure 4F), was unaltered. Hence, the liver contains an Mst1/2-dependent Yap1(Ser127) kinase that is entirely distinct from Lats1 and Lats2. Furthermore, consistent with the insignificant changes in Lats1/2 phosphorylation (Figures 4A and 4B), Lats1-catalyzed Yap1(Ser127) kinase activity is largely unaffected by Mst1/2 inactivation (Figure 4G).

Figure 3. Analysis of the Hippo Pathway in Mst1−/− Mst2−/− MEFs
(A) Western blot of immortalized MEFs grown to low (L) and high (H) density. Note that high density induces pYap1 regardless of Mst1/2 status. In contrast, pMob1 strictly requires Mst1/2. The MEFs were generated from wild type or Mst1−/− Mst2F/F mice and infected with a retrovirus expressing Cre recombinase. The cells were then immortalized by infection with a retrovirus expressing SV40 T Antigen.
(B) Western blot showing expression of full length (FL), amino terminal truncated (NT), and activated phosphorylated forms of Mst1 and Mst2 in liver and MEFs.
(C) Western blot showing that the induction of Lats1/2 activation loop (AL) phosphorylation in MEFs at high cell density does not require Mst1 or Mst2.
(D) Immunofluorescence showing that Yap1 (red) translocates out of the nucleus to the cytoplasm upon cellular confluence both in wild type and Mst1/2 null MEFs; scale bars represent 30 μm.

Mst1/Mst2 Deficiency in the Liver Leads to Resistance to Fas-Induced Apoptosis
Deregulation of the Hippo pathway in Drosophila and Yap1 over-expression in mice results in both hyperproliferative and antia apoptotic phenotypes (Zhao et al., 2008a). To test whether Mst1/2 deficiency affected hepatocyte apoptosis in addition to proliferation, we injected mutant mice and controls with anti-Fas antibody, Jo-2, 8 days after Adeno-Cre administration. Under these conditions, wild-type livers showed extensive hepatocyte apoptosis, whereas Mst1/2 null livers were strongly protected from cell death as determined by histological examination as well as by TUNEL staining and western blotting for cleaved caspase-3 (Figures 5A–5C).

Yap1 Is Required for Proliferation of Mst1/2 Mutant HCC Cell Lines
On the basis of the activation of Yap1 in mice with Mst1/2 inactivation in the liver and the similar liver phenotypes of these mice...
to those with transgenic hepatic overexpression of Yap1, we sought to assess whether Yap1 is critical for the tumorigenicity of Mst1/2 mutant HCC. To this end, we first tested whether Yap1 is under Mst1 regulation in an HCC cell line derived from the mouse model (designated HCC-1). We introduced lentiviruses expressing either GFP alone or in combination with Mst1 into HCC-1 cells; infection rates were reproducible 40%–60% as reflected by microscopy for GFP. Western blot analysis—of both unsorted cells or following GFP FACS—showed that Mst1 restored detectable Mob1 phosphorylation and induced pronounced phosphorylation of Yap1(Ser127) (Figure 6A). The fact that Lats1/2 phosphorylation was unaffected (Figures 6A and 6B) was in line with our earlier observation that acute inactivation of hepatic Mst1/2 has little impact on Lats1/2 carboxy-terminal phosphorylation in vivo (Figure 4A). Hence, Mst1/2 appear to regulate Yap1 in a Lats1/2-independent manner in hepatocytes and in these HCC cells. Notably, Lats1/2 is probably capable of phosphorylating Yap1(Ser127) in HCC1 cells inasmuch as H2O2—which strongly activated Lats1/2 in the Mst1/2 null HCC cells—induced a modest increase in Yap1(Ser127) phosphorylation (Figure 6B), presumably attributable in part to Lats1/2. The presence of Mst1, which was also activated by H2O2 (as demonstrated by the increased Mob1 phosphorylation), did not alter the extent of basal Lats1/2 activation, but
increase from 28.6% to 44.8%, whereas cells in S phase also showed decreases in expression of c-Myc expression and induction of caspase-3 cleavage (Figure 6F). These cells did cause further phosphorylation of Yap1 (Figure 6B). As expected, the increased Yap1 phosphorylation in the MST1-expressing HCC-1 cells resulted in decreased Yap1 nuclear residence as reflected by cell fractionation studies (Figure 6C). BrdU-DAPI labeling studies showed that Mst1 increased the proportion of HCC-1 cells in the G1 cell-cycle phase from 23% to 43% (Figure 6D). Mst1 restoration also led to a pronounced increase in the proportion of early apoptotic cells (13.97% versus 2.37%) and late apoptotic cells (5.78% versus 0.68%) (Figure 6E) and induction of caspase-3 cleavage (Figure 6F). These cells also showed decreases in expression of c-Myc expression and cyclins D3 and E (Figure 6F) and a marked reduction in cell proliferation, colony formation, and ability to grow in soft agar (Figure 6G and data not shown). Hence, Mst1 expression inactivates Yap1 and reverts the tumorigenic growth of HCC-1 cells.

To directly test whether Yap1 is required for tumor maintenance of Mst1/2 null HCC, we introduced lentiviruses expressing Yap1 shRNAs into HCC-1 cells. We find that Yap1 knockdown induced caspase 3 cleavage and a complete loss of c-Myc polypeptide as well as decreased expression of cyclin D3 and cyclin E (Figure 7A). Yap1 shRNA expressing cells show a pronounced alteration in cell cycle distribution (Figure 7B); cells in G1 increase from 28.6% to 44.8%, whereas cells in S phase decrease from 56.8% to 36.55%. Yap1 depletion resulted in a high level of apoptosis (Figure 7C; 28.47% versus 1.62% early apoptosis; 4.44% versus 1.02% late apoptosis). The Yap1-deficient cells are unable to form colonies at low density, to sustain proliferation, or to grow in soft agar (Figures 7D–7F). These data indicate that Yap1 is necessary to both sustain proliferation and suppress apoptosis in Mst1/2 null HCC. Thus Mst1/2-dependent phosphorylation and inactivation of Yap1 is critical for tumor suppression in the liver.

**pYAP1, pMOB1, and the Cleaved, Active MST1 Catalytic Fragment Are Frequently Lost in Human HCCs**

Previous studies have reported that MST1/2 activity and expression of the candidate MST1/2 regulators RASSF1A and NORE1B are reduced in most human HCCs compared to normal liver (Calvisi et al., 2006; Macheiner et al., 2009). Moreover, whereas Yap1 is exclusively cytoplasmic in the normal liver, it has been reported that ~50% of human HCC specimens exhibit nuclear staining for Yap1 (Dong et al., 2007; Zhao et al., 2007). Based on these data and our observation that loss of Yap1(Ser127) phosphorylation due to Mst1/2 inactivation results in nuclear translocation of Yap1 in the mouse liver, we sought to address whether pYAP1(Ser127) is lost in human HCC and therefore may contribute to its pathogenesis. To this end, we analyzed expression of MST1/2-YAP1 signaling components in a series of matched HCC and normal liver specimens by immunoblotting (Figure 8). As in the mouse liver, all normal human liver specimens exhibited robust expression of total YAP1 and pYAP1(Ser127). The MOB1 polypeptide immunoblot visualizes two closely spaced bands with the upper predominant (Figure 8); on p-MOB1 immunoblot, the lower band is usually the predominant signal. MST1 and MST2 are readily visualized by immunoblot and in 19/21 normal livers and a substantial fraction of MST1 is present as a cleaved 34 kDa polypeptide (Figure 8), corresponding to the pattern seen in normal mouse liver. These patterns are significantly altered in the majority of HCCs. First, Yap1(Ser127) phosphorylation is markedly reduced or absent in 7/21 HCCs (2, 3, 5, 10, 11, 13, and 15); moreover, in four HCCs (4, 6, 12, and 15) the level of total YAP1 polypeptide is substantially elevated. Thus, in nearly half of these unselected HCCs, YAP1 is underphosphorylated and/or overexpressed, both circumstances likely to promote YAP1 nuclear localization as previously reported. In all but six of the HCCs (1, 6, 7, 13, 14, and 21), the level of p-MOB1 is markedly reduced as compared to the normal liver. Inasmuch as MOB1 is a highly specific MST1/2 substrate, this argues for a marked reduction in MST1/2 kinase activity (and/or increase in MOB1-phosphatase activity) in these HCCs. Expression of the MST1 and MST2 56–60 kDa polypeptides is well preserved in the HCCs (except in 7 and 21); however, in 13/21 HCCs, the 34 kDa MST1 polypeptide is absent despite its ready visualization in the paired normal liver. We have not assayed directly MST1/2 kinase in these samples, and immunoblotting of these lysates with anti-MST1/2(p-Ser183/180) exhibits numerous nonspecific bands near 55–60 kDa and 34 kDa, precluding this estimate of MST1/2 kinase activity. Nevertheless, the lack of the 34 kDa constitutively active catalytic fragment, which is the predominant active form of MST1/2 in normal mouse liver, may contribute to a lowered MST1/2 activity in these HCCs. It is notable that all...
but one (13) of the seven HCCs with diminished pYAP1 exhibit diminished p-MOB1 and 5/7 lack expression of the MST1 34 kDa fragment (3, 5, 11, 13, and 15). Hence, loss of negative regulation of YAP1, most often due to diminished MST1/2 activity, is a common occurrence and likely pathogenetic factor in human HCC.

**DISCUSSION**

We have demonstrated that Mst1 and Mst2 act in a redundant manner to maintain quiescence in the adult liver and that their dual inactivation leads to immediate Yap1 activation, liver overgrowth, resistance to Fas-induced apoptosis, and rapid HCC development. We provide evidence that Yap1 nuclear residence and activation, resulting from loss of Ser127 phosphorylation, is critical for HCC development and maintenance in the setting of Mst1/2 deficiency. In addition, defects in MST1/2-YAP1 signaling are present in a subset of human HCCs.

The ability of Mst1/2 to regulate Yap1(Ser127) phosphorylation is anticipated by the “Hippo” paradigm. The present data indicate, however, that in the liver Mst1/2 controls Yap1 phosphorylation through a kinase other than Lats1/2. This and other recent work in Mst1/2-deficient mice illustrate two noteworthy features of Mst1/2 signaling. First, in all cellular contexts examined thus far, loss of Mst1/2 signaling and Yap1 phosphorylation exhibit an unexpected diversity in addition to the relationships predicted by the *Drosophila* Hippo-Lats-Yorkie tumor-suppressor pathway. Thus, in mouse liver, Mst1/2 controls Yap1 nuclear residence and activation, resulting from loss of Ser127 phosphorylation, is critical for HCC development and maintenance in the setting of Mst1/2 deficiency. In addition, defects in MST1/2-YAP1 signaling are present in a subset of human HCCs.
MEFs achieving confluence exhibit activation of Lats1/2, Yap1 phosphorylation, and egress of Yap1 from the nucleus; however, these events are unaltered despite the deletion of Mst1 and Mst2 and the loss of Mob1 phosphorylation. Therefore, it is clear that Mst1/2-Lats1/2-Yap1 signaling varies according to cell type and cell context; there exist Lats1/2 activators other than Mst1/2 and Yap1(Ser127) kinases other than Lats1/2. It is also apparent that important Mst1/2 substrates apart from Mob1, 

Figure 7. Yap1 Is Required for Tumorigenicity of Mst1/2 Null HCC Cells
(A) Western blots of lysates from HCC 1 cells infected with lentiviruses expressing scrambled or Yap1 shRNAs and analyzed at day 6 post infection. Yap1 shRNA silences Yap1 expression and results in caspase 3 cleavage (CL) and reduction in full length (FL) caspase 3. 
(B) BrdU/DAPI staining and flow cytometry. Yap1 shRNA increases the proportion of HCC 1 cells in G1 (bottom left quadrant) and decreases cells in S phase (top quadrant). 
(C) Annexin V/7 AAD staining and flow cytometry. Yap1 shRNA induces early apoptosis (bottom right quadrant) and late apoptosis (top right quadrant). 
(D) HCC 1 cells expressing Yap1 shRNA are unable to form colonies in clonogenic assays. 
(E and F) Yap1 knockdown prevents the proliferation of HCC 1 cells as determined by MTT assay (E) and suppresses growth in soft agarose (F).
phosphorylation as being an important mechanism for YAP1. On the other hand, the present work points toward loss of YAP1(Ser127) phosphorylation in ~30% of HCC specimens (Figure 8). Significantly, we observed a close correlation between loss of pYAP1(Ser127) and loss of pMOB1(Thr12) in the human HCC specimens, indicating that low MST1/2 activity is likely responsible for most instances of low YAP1(Ser127) phosphorylation. Further studies will be required to demonstrate directly the functional contributions of MST-YAP1 signaling defects to human HCC pathogenesis.

Although our work suggests that Yap1 is a major mediator of phenotypes downstream of Mst1/2 in the liver, we cannot rule out the possibility that there are other critical effectors of the pathway that contribute to these phenotypes. In this regard, it is notable that the transcriptional coactivator Taz, a potential oncogene (Chan et al., 2008; Lei et al., 2008), shares 45% homology to Yap1 throughout its sequence, and in vitro studies suggest that these proteins can be regulated through comparable mechanisms (i.e., by Lats-mediated phosphorylation of a conserved motif resulting in cytoplasmic sequestration) (Lei et al., 2008). We find that Taz phosphorylation at this site is reduced following Mst1/2 inactivation in the liver (Figure S4A), suggesting that Taz is negatively regulated by Mst1/2. However, levels of Taz polypeptide are also decreased in the Mst1/2 liver and in HCC, indicating that Taz is unlikely to play a positive role in overproliferation or tumorigenesis in this setting.

Our data show that Mst1/2 are constitutively active in the quiescent liver and that they mediate sustained phosphorylation of Mob1 and Yap1. A key outstanding question is the nature of the upstream activating signals in this pathway. The importance of this question is emphasized by the finding that despite the frequent loss of pMOB and pYAP1 in human HCCs, the expression of the full-length MST1 and MST2 polypeptides is maintained in nearly all these tumors. Consequently, it is likely that diminished upstream inputs are the basis for deficient MST1/2 activity in these tumors. Three apparently independent mechanisms for upstream regulation of the Mst1/2 kinases have been identified thus far. In the Drosophila Hippo pathway, the activity of the Mst1/2 ortholog, Hippo, is controlled, at least in part, by cell-cell contact, mediated by the atypical cadherin, Fat, and the membrane-associated FERM-domain polypeptides, Expanded and Merlin (Reddy and Irvine, 2008). In mammals, NF2/MERLIN has been reported to regulate YAP1 cytoplasmic retention in neural tumor-derived cell lines (Zhao et al., 2007). Similarly, overexpression of FRMD6, the closest mammalian homolog of Expanded, can repress the activity of a Yap1 transcriptional reporter (Zhao et al., 2007). However, the physiological significance of this pathway and its role in the regulation of Mst1/2 in liver has not been defined. A second mechanism for Mst1/2 activation involves ligand-mediated receptor signaling and the Rassf1/Nore proteins that are found in a constitutive complex with Mst1/2 in cell lines that express these polypeptides (Avruch et al., 2009). In T cells, Mst1 is activated by stimulation of antigen or chemokine receptors, which induce association of the Nore1B/Mst1 complex with activated Ras-like GTPases, specifically Rap1 and Rap2. The Nore1B/Mst1 complex is required in T cells for Rap1-GTP-induced integrin clustering and in naive T cells for restraint of proliferation. Hippo pathway components (e.g., a cadherin, ERM proteins, or WW45) are not involved in the GTPase regulation of the Nore1/Mst1 complex. Inasmuch as RASSF1A, NORE1A, and NORE1B have been shown to be epigenetically inactivated in wide range

Lats1/2, and Ndr1/2 (Vichalkovski et al., 2008) remain to be discovered.

Previous reports have shown that Yap1 overexpression in mice promotes the development of HCC (Dong et al., 2007; Zender et al., 2006) and that increased nuclear abundance of Yap1 is present in about 50% of human HCCs (Dong et al., 2007; Zhao et al., 2007). The mechanisms of Yap1 deregulation in human HCCs were not defined in these studies. Although amplification of the Yap1 locus may lead to Yap1 overexpression in some HCCs, such amplification appears to be relatively uncommon, restricted to ~5%–10% of tumors (Zender et al., 2006). On the other hand, the present work points toward loss of Yap1(Ser127) phosphorylation as being an important mechanism for Yap1 deregulation in human HCC, as we have observed this alteration.
of human tumors including HCC (Calvisi et al., 2006; Donninger et al., 2007; Macheiner et al., 2009) it is plausible that their diminished expression might result in defective regulation of MST1/2 signaling.

A third mechanism of MST1/2 regulation, probably operational in the liver, appears to be at the level of caspase-dependent cleavage. Previous studies have shown that MST1 and MST2 exist as 56 kDa full-length polypeptides or as truncated 34–36 kDa amino-terminal forms that arise due to caspase-dependent cleavage during apoptosis (Graves et al., 1998; Lee et al., 2001). We find that the majority of MST1 in normal mouse liver exists as a 34–40 kDa polypeptide, and a significant fraction of MST2 is also found in a truncated form. Moreover, the vast majority of the activated MST1/2 kinase in liver (i.e., forms phosphorylated at the activation loop) are the short MST1/2 polypeptides, whereas spleen and MEFs exhibit only the presence of the full-length forms. Hence the cleavage of MST1/2 appears to be a regulated, tissue-specific process. The truncated forms have lost their autoinhibitory and SARAH domains, are thus highly active, and are released from upstream regulation by the WW45 or RasS family polypeptides. The truncated MST1/2 polypeptides are preferentially localized to the nucleus and have an altered substrate specificity (Anand et al., 2008; Ura et al., 2001); however, their potency in regulation of Yap1 as compared to the full-length MST1/2 polypeptides remains to be defined. The proportion of MST1 exhibiting cleavage in the liver is much higher than that of MST2. In addition, MST1/2−/− livers exhibit a significant reduction in pYap1 and pMob1 compared to wild-type livers, whereas there is only a modest decrease in pYap1 in pMob1 in MST2−/− livers (Figure S7). Hence, although both MST1 and MST2 are required for complete loss of Yap1 phosphorylation in the liver, MST1 plays the more important role. Caspase-3-dependent cleavage of MST1 is required for myoblast differentiation in vitro, in the absence of any detectable apoptosis (Fernando et al., 2002; Murray et al., 2008). This observation is in keeping with emerging data from embryonic stem cells and hematopoietic stem cells showing that caspase-3 activation may generally contribute to cellular differentiation through proteolysis of multiple targets (Yi and Yuan, 2009). Thus, we surmise that the truncated, constitutively active form of MST1/2 may play an important role in maintenance of hepatocytes in a differentiated, nonproliferative state.

Our data also demonstrate the importance of endogenous MST1/2 in apoptotic regulation in an intact mammalian organism, consistent with the loss of developmental apoptosis seen with Drosophila Hippo loss of function (Figure 5). As to the mechanism MST1/2-dependent apoptosis, the Jo-2 anti-Fas antibody does cause a small increase in Mob1 phosphorylation indicative of MST1/2 activation, but surprisingly is accompanied by a reduction in Yap1 phosphorylation (Figure S8). Thus, whether and to what extent the modest activation of MST1/2 by the Fas agonist contributes to the rapid activation of apoptosis by Fas is unclear. The protective effect of MST1/2 ablation against Fas-induced apoptosis seems more likely to reflect enhanced expression of Yap1-dependent transcriptional outputs that confer resistance to apoptosis (Zhao et al., 2008b).

HCC is the fifth most common malignant neoplasm worldwide and third most frequent cause of cancer-related death (Llovet et al., 2003). Only a minority of patients are eligible for potentially curative surgery and conventional chemotherapeutic approaches are ineffective in this disease (Villanueva et al., 2008). While molecularly targeted agents have increased survival in patients with advanced HCC, only a subset of patients show responses and these agents do not achieve cures. It is clear that a better definition of the molecular pathogenesis of HCC and the molecular classification of subsets of tumors is important steps in the design of improved therapeutic strategies. Our work shows that loss of YAP1 phosphorylation specifies of a subset of human HCC. In addition, we have observed that, as in the murine HCCs, YAP1 knockdown in some human HCC cell lines blocks colony formation in vitro and promotes apoptosis (data not shown). Hence, elucidating the critical YAP1 target genes may point to effective therapeutic targets for a subset of HCC. In future studies, it will also be important to define whether loss of YAP1 phosphorylation is associated with other well-defined molecular alterations in HCC and to determine what is the prognostic significance of this subgroup of tumors.

**EXPERIMENTAL PROCEDURES**

**Animals**

The generation of the MST2F and MST2−/− alleles and the analysis of the MST1+/−, MST2−/− embryos are described in detail in the Supplemental Experimental Procedures. All mice used in this study were maintained on a mixed genetic background (C57BL/6; 129/Sv). Mouse work was done with Institutional Animal Care and Use Committee approval and in strict accord with good animal practice as defined by the Office of Laboratory Animal Welfare.

**Materials and Reagents**

Antibodies against MST1, MST2, pMST1 (Thr183P)/pMST2 (Thr180P), Lats1, pLats carboxy terminal, pLats AL, Mob1, and pMob1(Thr12) were described previously (Praskova et al., 2008). All other antibodies and assay reagents were obtained from commercial sources as described in Supplemental Experimental Procedures. AdSCMVCre (Ad Cre) virus was purchased from the Gene Transfer Vector Core at the University of Iowa.

**Cell Culture and Molecular Methods**

Methods for cell culture, adenoviral and lentiviral mediated gene transfer, subcellular fractionation, immunoblotting, immunofluorescence, histochemistry, assays for cell proliferation, apoptosis, and mRNA abundance are described in Supplemental Experimental Procedures.

**Hepatic Yap1(Ser127) Kinase Activities**

Fresh mouse livers were homogenized in 20 mM Tris HCl (pH 7.6), 0.3 M sucrose, 1 mM EDTA, 5 mM EGTA, 1 mM DTT, 2.5 mM sodium pyrophosphate, and 1 mM L-glycerophosphate, containing a proteinase inhibitors tablet (Roche). The supernatant of a 100,000 × g, 2 hr centrifugation was applied to a HiTrap HP Q column (GE Healthcare) equilibrated in 20 mM Tris HCl (pH 7.6), 1 mM EDTA, and 1 mM NaF. Elution was carried out with 4 column volumes of an NaCl gradient from 0.1 M to 0.6 M. Forty fractions were collected and an aliquot of each was assayed for Yap1(Ser127) kinase activity by incubation with prokaryotic recombinant GST Yap, 10 mM Mg, and 100 μM ATP for 30 min at 30°C. The kinase reactions were stopped by adding SDS sample buffer and subjected to SDS PAGE and immunoblot as indicated.

**Human Liver and HCC Samples**

Human samples were obtained under informed consent from the Foundation for Human Tissue and Cell Research (HTCR), Regensburg, Germany. Experiments were performed under HTCR and Massachusetts General Hospital Institutional Review Board approval and are considered exempt. Biopsies from specimens of normal liver tissue (distant from the tumor) and HCC were collected snap frozen. Patients receiving hepatotoxic medication or chemotherapy or patients with systemic disease known to affect the liver...
were excluded. Diagnosis of HCC and normal liver was confirmed based on histological findings by independent pathologists.

SUPPLEMENTAL DATA

Supplemental Data include Supplemental Experimental Procedures, one table, and eight figures and can be found with this article online at http://www.cell.com/cancer-cell/supplemental/S1535-6108(09)00337-7.

ACKNOWLEDGMENTS

This work was supported in part by DK17776 (J.A.), K01CA104647, the Sidney Kimmel Foundation for Cancer Research (N.B.), the Linda J. Verville Cancer Research Foundation (B.P.), and institutional funds. D.Z. is supported by T32DK007028. The study was designed by J.A., D.Z., and N.B. and carried out by D.Z., with contributions from C.C., J.S.P., F.X., Y.Y., B.P., and G.Y.L. N.B. and J.A. wrote the manuscript with contributions by D.Z., C.C., B.P., and J.T.L. W.T. provided essential materials. The authors thank S. Liehhaber for analysis of the human HCC data, T. Weiss (University of Regensburg, Germany) for human liver samples used in preliminary studies, and R.T. Bronson for histologic analyses.

Received: May 6, 2009
Revised: August 14, 2009
Accepted: September 22, 2009
Published: November 2, 2009

REFERENCES


